```html

Japanese Bowel Cancer (Stomach Cancer) – A Comprehensive Medical Guide

Overview

Stomach cancer (also called gastric cancer) arises when malignant cells develop in the lining of the stomach. In Japan, the disease has historically been more common than in most Western countries, earning the informal term “Japanese bowel cancer.” The high incidence is linked to dietary patterns, Helicobacter pylori infection rates, and genetic factors.

Who it affects: It most often occurs in adults over 50, with a male‑to‑female ratio of about 2:1. According to the CDC and World Cancer Research Fund, Japan reports roughly 70 cases per 100,000 people each year—one of the world’s highest rates.

Prevalence: In 2022, Japan recorded ~121,000 new gastric‑cancer cases and ~30,000 deaths, representing ~15 % of all global gastric‑cancer deaths despite having only 1.6 % of the world’s population (IARC 2023).

Symptoms

Early gastric cancer often produces vague or no symptoms, which is why screening is vital in high‑risk populations. When symptoms appear, they may include:

• Persistent indigestion or heartburn – a burning sensation that does not improve with antacids.
• Upper‑abdominal pain or discomfort – may be dull, gnawing, or cramping.
• Feeling full after eating a small amount – known as early satiety.
• Unexplained weight loss – often 5 % or more of body weight over a few months.
• Nausea or vomiting – especially when food sticks in the stomach.
• Vomiting blood (hematemesis) – bright red or coffee‑ground appearance.
• Dark, tar‑like stools (melena) – indicates digested blood from the stomach.
• Loss of appetite – even favorite foods become unappealing.
• Fatigue or weakness – often from anemia caused by chronic bleeding.
• Swelling of the abdomen – may suggest tumor growth blocking stomach emptying.

Because many of these signs overlap with common gastrointestinal disorders (e.g., gastritis, ulcer disease), any persistent symptom lasting > 4 weeks warrants medical evaluation.

Causes and Risk Factors

Stomach cancer is multifactorial. No single cause can be identified in most patients, but the following increase risk:

Infection

• Helicobacter pylori – a bacterium that causes chronic gastritis and ulcers; it accounts for up to 70 % of gastric cancers worldwide (Mayo Clinic).

Dietary factors

• High intake of salted, smoked, or pickled foods (common in traditional Japanese cuisine) – these contain nitrosamines, known carcinogens.
• Low consumption of fresh fruits and vegetables – antioxidants may protect stomach lining.
• Excessive alcohol use – especially combined with smoking.

Environmental & lifestyle

• Smoking – doubles the risk; the risk declines after quitting but never returns to baseline.
• Obesity – waist circumference > 90 cm in men and > 80 cm in women is linked to increased gastric‑cardia cancers.

Genetic and medical history

• Family history of gastric cancer or hereditary diffuse gastric cancer (CDH1 gene mutation).
• Previous gastric surgery (e.g., for ulcers) – alters stomach environment.
• Chronic atrophic gastritis or intestinal metaplasia.
• Blood type A – has a modestly higher risk.

Diagnosis

When a clinician suspects gastric cancer, a step‑wise approach is used:

Initial evaluation

• Medical history & physical exam – focus on weight loss, anemia, and abdominal tenderness.
• Laboratory tests – complete blood count (CBC) for anemia, serum vitamin B12, and iron studies.

Imaging and endoscopic studies

• Upper gastrointestinal (GI) endoscopy – gold standard; allows direct visualization and biopsy of suspicious lesions. In Japan, endoscopic screening starts at age 50 for men and 60 for women (Japanese Gastric Cancer Association, 2022).
• Endoscopic ultrasound (EUS) – assesses depth of tumor invasion and nearby lymph nodes.
• Contrast‑enhanced CT scan of the chest, abdomen, and pelvis – evaluates distant spread (metastasis).
• Positron emission tomography (PET) scan – sometimes used for staging when CT is equivocal.
• Upper GI series (barium swallow) – rarely used now but can show obstruction.

Pathology

Biopsy samples are examined for histologic type (intestinal vs. diffuse), grade, and presence of HER2 over‑expression, which guides targeted therapy.

Staging

The AJCC (American Joint Committee on Cancer) TNM system is used internationally. Staging determines treatment intensity and prognosis.

Treatment Options

Treatment is individualized based on stage, tumor location, patient fitness, and personal preferences. The main modalities are:

Surgery

• Curative gastrectomy – removal of part (distal) or whole (total) stomach with adjacent lymph nodes. In Japan, a D2 lymph‑node dissection (removal of nodes along the major arteries) is standard.
• Minimally invasive approaches – laparoscopic or robotic gastrectomy reduces recovery time and postoperative pain.
• Endoscopic submucosal dissection (ESD) – for very early cancers confined to the mucosa, preserving the stomach.

Radiation therapy

• Often combined with chemotherapy (chemoradiation) for locally advanced disease or as adjuvant therapy after surgery.

Chemotherapy

• Neoadjuvant (pre‑operative) chemotherapy – regimens such as S‑1 plus oxaliplatin (SOX) or capecitabine + cisplatin improve resection rates.
• Adjuvant (post‑operative) chemotherapy – capecitabine + oxaliplatin (CAPOX) is standard for stage II‑III disease in Japan (Sasaki et al., 2020).
• Targeted therapy – trastuzumab for HER2‑positive tumors, and ramucirumab or pembrolizumab for selected advanced cases.

Immunotherapy

PD‑1 inhibitors (nivolumab, pembrolizumab) have shown survival benefits in third‑line settings, especially in tumors with high microsatellite instability (MSI‑H) or PD‑L1 expression.

Supportive and palliative care

• Nutrition support (enteral feeding tubes, dietitian counseling).
• Palliative radiation for bleeding or obstruction.
• Pain control, anti‑nausea medication, and psychosocial support.

Lifestyle changes

Smoking cessation, limiting alcohol, and a diet rich in fresh produce are recommended throughout treatment to improve tolerance and outcomes.

Living with Japanese Bowel Cancer (Stomach Cancer)

Living with gastric cancer involves medical, nutritional, and emotional adjustments.

Nutrition

• Eat small, frequent meals – 5‑6 times per day – to reduce early satiety.
• Choose soft, low‑fat, low‑fiber foods during recovery (e.g., broths, pureed vegetables, tofu). Gradually re‑introduce fiber as tolerated.
• Include protein‑rich foods (lean fish, soy, eggs) to preserve muscle mass.
• Consider a multivitamin with B12 and iron if labs show deficiency.
• Stay hydrated – sip water throughout the day.

Physical activity

Moderate activity (30 minutes of walking, light stretching) most days improves fatigue and quality of life. Check with your oncologist before starting a new exercise program.

Follow‑up schedule

• First 2 years after curative treatment: visits every 3–6 months with physical exam, CBC, and CT scan if indicated.
• Years 3‑5: every 6–12 months.
• Long‑term: annual visits, especially if you had high‑risk pathology.

Emotional support

Join a support group (many hospitals in Japan have “癌サポート” groups), talk with a counselor, or use online resources such as Cancer.Net. Mental health is a vital component of recovery.

Prevention

While you cannot change your genetics, several evidence‑based actions meaningfully lower risk:

• Eradicate H. pylori – testing and treatment (triple therapy) is recommended for anyone with a history of ulcers or who is over 40 in high‑prevalence areas.
• Adopt a plant‑forward diet – aim for ≥5 servings of fruits/vegetables daily, and limit salty, smoked, or pickled foods.
• Maintain a healthy weight – BMI 18.5–24.9.
• Avoid tobacco – use cessation programs, nicotine replacement, or prescription medications.
• Limit alcohol – ≤ 1 drink per day for women, ≤ 2 for men.
• Screening endoscopy – recommended for individuals ≥ 50 years in Japan, especially those with a family history or prior H. pylori infection.

Complications

If not detected early, stomach cancer can lead to serious complications:

• Bleeding – chronic or acute hemorrhage causing anemia or life‑threatening hemorrhage.
• Gastric outlet obstruction – tumor blocks the pylorus, causing vomiting and severe malnutrition.
• Peritoneal carcinomatosis – spread of cancer cells throughout the abdominal cavity.
• Liver or lung metastases – common sites of distant spread.
• Malnutrition and cachexia – due to reduced intake and metabolic changes.
• Post‑surgical complications – anastomotic leak, infection, or dumping syndrome (rapid gastric emptying).

When to Seek Emergency Care

---

**Sources**: Mayo Clinic, CDC, National Cancer Institute, World Health Organization, Japanese Gastric Cancer Association guidelines, IARC Cancer Fact Sheets, peer‑reviewed journals (e.g., Gastric Cancer, JAMA Oncology).

```